Skip to Content

Study: CPAP therapy can improve lifespan

Study: CPAP therapy can improve lifespan

LYON, France – Using PAP therapy can significantly increase sleep apnea patients’ chances of living longer, according to an abstract presented this week at the virtual European Respiratory Society (ERS) International Congress 2021 and supported by ResMed. 

The landmark ALASKA study, “CPAP Termination and All-Cause Mortality: a French Nationwide Database Analysis,” concluded people with obstructive sleep apnea who continued PAP therapy were 39% more likely to survive than OSA patients who didn’t. Researchers observed more than 176,000 people in France with sleep apnea over a three-year period. Study authors say the survival rate gap remained significant when accounting for patients’ ages, overall health, other pre-existing conditions and causes of death. 

“Treating sleep apnea with PAP therapy may help you live longer; that’s the key takeaway here for people with sleep apnea and their doctors,” said Adam Benjafield, study co-author and ResMed Vice President of Medical Affairs. “This finding underscores how critical it is to identify the hundreds of millions of people worldwide whose sleep apnea is undiagnosed and untreated.” 

An estimated 936 million people worldwide have sleep apnea – including more than 175 million Europeans – but more than 80% remain undiagnosed. 

The ALASKA study was conducted in partnership with Professor Jean-Louis Pépin; universities of Grenoble, San Diego, and Sydney; Sêmeia; and other researchers from ResMed’s industry-academia collaboration medXcloud.


To comment on this post, please log in to your account or set up an account now.